TITLE

Ewing's sarcoma

AUTHOR(S)

Karosas, Ann O.

PUB. DATE

October 2010

SOURCE

American Journal of Health-System Pharmacy;10/1/2010, Vol. 67 Issue 19/20, p1599

SOURCE TYPE

Academic Journal

DOC. TYPE

Article

ABSTRACT

Purpose. The current treatments of and new therapeutic options for the management of Ewing's sarcoma (ES) are reviewed. Summary. ES is the second most common primary bone malignancy in pediatric patients and is numbered among the cancers that result in the greatest risk of mortality and morbidity in children and young adults. Much progress has been made in the treatment of ES since the disease was first described in the 1920s. With current multimodality treatment including chemotherapy, radiation, and surgery, patients with localized disease have a long-term survival rate of approximately 50%. Survival rates for patients with metastatic disease or those with early relapse remain poor. New combinations of cytotoxic agents such as cyclophosphamide, topotecan, irinotecan, and temozolomide have shown efficacy and tolerability in patients with relapsed or refractory disease. To date, the role of high-dose chemotherapy supported by stem cell rescue as a consolidation therapy for high-risk ES tumors has yet to be conclusively determined. Much effort is being invested in treating cancer with targeted therapies, and the EWS-ETS fusion gene would likely provide an important tumorspecific target. Tyrosine kinases (TKs) are overexpressed in human sarcoma tumors, and cell lines may serve as potential targets for new therapies. One TK receptor that is a promising therapeutic target is insulinlike growth factor-1 receptor. Conclusion. Treatments for ES include surgery, radiation, and cytotoxic regimens, many of which include vincristine. Treatment for recurrent ES has included topotecan, cyclophosphamide, temozolomide,and irinotecan. Angiogenesis inhibitors, TK inhibitors, and bisphosphonates have also been studied.

ACCESSION #

53924599

 

Related Articles

• Potential use of Imatinib in Ewing's Sarcoma: Evidence for In Vitro and In Vivo Activity. Merchant, Melinda S.; Chan-Wook Woo; Mackall, Crystal L.; Thiele, Carol J. // JNCI: Journal of the National Cancer Institute;11/20/2002, Vol. 94 Issue 22, p1673 

  Background: Ewing's sarcoma cells express c-kit, a receptor tyrosine kinase, and its ligand, stem cell factor (SCF), creating a potential autocrine loop that may promote tumor survival. We thus examined whether the specific tyrosine kinase inhibitor imatinib mesylate (hereafter imatinib;...

• The emerging quest for the optimal angiostatic combination therapy. Griffioen, Arjan W.; Weiss, Andrea; Berndsen, Robert H.; Abdul, U. Kulsoom; te Winkel, Marije T.; Nowak-Sliwinska, Patrycja // Biochemical Society Transactions;Dec2014, Vol. 42 Issue 6, p1608 

  Angiostatic therapies are now routinely embedded in the daily clinical management of cancer. Although these agents clearly benefit patient survival rates, the effect is only moderate with sometimes considerable side effects. A major cause of failure in this respect is the induction of resistance...

• Imatinib and docetaxel in combination can effectively inhibit glioma invasion in an in vitro 3D invasion assay. Kinsella, Paula; Clynes, Martin; Amberger-Murphy, Verena // Journal of Neuro-Oncology;Jan2011, Vol. 101 Issue 2, p189 

  The main problem in the treatment of malignant astrocytomas is their invasive behaviour. Successful resection of the main tumour mass cannot prevent recurrence due to single cells invading the surrounding brain parenchyma at the time of diagnosis. The classical combination therapy, PCV...

• Clinical effect of imatinib added to intensive combination chemotherapy for newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Lee, K.-H.; Lee, J.-H.; Choi, S.-J.; Seol, M.; Lee, Y.-S.; Kim, W.-K.; Lee, J.-S.; Seo, E.-J.; Jang, S.; Park, C.-J.; Chi, H.-S. // Leukemia (08876924);Sep2005, Vol. 19 Issue 9, p1509 

  Clinical impact of imatinib was evaluated in 20 patients (median age, 37 years; range, 15–67 years) with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL), who were administered with induction chemotherapy of daunorubicin, vincristine, prednisolone,...

• Treatment of metastatic renal cell carcinoma and renal pelvic cancer. Tanji, Nozomu; Yokoyama, Masayoshi // Clinical & Experimental Nephrology;Jun2011, Vol. 15 Issue 3, p331 

  better understanding of the molecular biology of renal cell carcinoma (RCC) and the emergence of molecular targeted drugs have revolutionized the treatment for patients with metastatic RCC (mRCC). Multi-targeted tyrosine kinase inhibitors (sorafenib and sunitinib) and mammalian target of...

• Anti-Angiogenic Approaches to Malignant Gliomas. Soffietti, R.; Trevisan, E.; Bertero, L.; Bosa, C.; Rudà, R. // Current Cancer Drug Targets;Mar2012, Vol. 12 Issue 3, p279 

  Despite advances in multidisciplinary approaches, the prognosis for most patients with malignant gliomas is poor. Malignant gliomas are highly vascularized tumors with elevated expression of vascular endothelial growth factor (VEGF), an important mediator of angiogenesis. Recent studies of...

• EGFR(s) in Aging and Carcinogenesis of the Gastrointestinal Tract. Nautiyal, Jyoti; Kanwar, Shailender Singh; Majumdar, Adhip P. N. // Current Protein & Peptide Science;Sep2010, Vol. 11 Issue 6, p436 

  No abstract available.

• Systems Analysis of Drug-Induced Receptor Tyrosine Kinase Reprogramming Following Targeted Mono- and Combination Anti-Cancer Therapy. Goltsov, Alexey; Deeni, Yusuf; Khalil, Hilal S.; Soininen, Tero; Kyriakidis, Stylianos; Huizhong Hu; Langdon, Simon P.; Harrison, David J.; Bown, James // Cells (2073-4409);Jun2014, Vol. 3 Issue 2, p563 

  The receptor tyrosine kinases (RTKs) are key drivers of cancer progression and targets for drug therapy. A major challenge in anti-RTK treatment is the dependence of drug effectiveness on co-expression of multiple RTKs which defines resistance to single drug therapy. Reprogramming of the RTK...

• A case of metastatic breast cancer successfully treated with lapatinib plus capecitabine therapy. Kefeli, Umut; Bilici, Ahmet; Ustaalioglu, Bala; Kefeli, Aysegul; Yildirim, Mahmut; Seker, Mesut; Gumus, Mahmut // Archives of Gynecology & Obstetrics;Feb2011, Vol. 283 Issue 2, p405 

  No abstract available.

Read the Article